Mylan Pharmaceuticals, Inc.
Records under this name other than the patents Mylan Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Back to Mylan Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,450,487 | Process for the Preparation of CIS-2-Methylspiro (1, 3-Oxathiolane 5-3') Quinuclidine Formerly held In force · High confidence | In force | High confidence | |
| US 9,493,473 | Processes for Making Ponatinib and Intermediates Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,034,714 | Process of Making Regadenoson and Novel Polymorphs Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,442,832 | Process of Making Regadenoson and Novel Polymorph Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,392,417 | Novel Polymorph of Regadenoson and Process for Preparation Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,519,121 | Process and Novel Polymorphic Form of Vortioxetine and Its Pharmaceutically Acceptable Salts Formerly held In force · High confidence | In force | High confidence | |
| US 10,221,184 | Novel polymorphs of ponatinib hydrochloride Formerly held In force · High confidence | In force | High confidence | |
| US 10,844,103 | Method for the Purification of G-CSF Formerly held Term ended Term ended Jul 14, 2026 · High confidence | Term ended | Term ended Jul 14, 2026 | High confidence |
| US 9,815,879 | Method for the Purification of G-Csf Formerly held Lapsed on the fee record Ended Nov 14, 2025 · High confidence | Lapsed on the fee record | Ended Nov 14, 2025 | High confidence |
| US 9,205,062 | Transdermal Systems Containing Multilayer Adhesive Matrices to Modify Drug Delivery Term ended Term ended Aug 6, 2025 · High confidence | Term ended | Term ended Aug 6, 2025 | High confidence |